Partner Randy D. Gordon, chair of the Firm’s antitrust and trade regulation practice, authored an article for Law360 regarding the antitrust issues associated with the Bayer-Monsanto deal.
“Bayer can make a credible case that it and Monsanto are not — for the most part — competitors in the two market dimensions that count in any antitrust analysis. First, with respect to product markets, Bayer has focused on herbicides in the agricultural space, whereas Monsanto has focused on seeds and genetic technology.”
Subscribers can access the full article here.
Related Insights
August 8, 2025
Foley Ignite
The Rise of "Acquihiring" in a Post-Layoff Tech Sector
As a practicing M&A attorney representing both strategic acquirers and venture-backed targets, I have had a front row seat to the…
August 7, 2025
Manufacturing Industry Advisor
Tariffs and Your Contracts: Why do pricing and tax provisions matter?
President Trump’s shakeup of U.S. trade policy with its approach to tariffs is costing companies billions of dollars.
August 7, 2025
Foley Viewpoints
USPTO Addresses Reports of New Patent Fee Structure
In a recent webinar hosted by the Licensing Executives Society, U.S. Patent and Trademark Office acting Director Coke Morgan Stewart…